<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01371162</url>
  </required_header>
  <id_info>
    <org_study_id>NP25733</org_study_id>
    <nct_id>NCT01371162</nct_id>
  </id_info>
  <brief_title>A Study of RO5428029 in Healthy Volunteers and Patients With Chronic Hepatitis C</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of the HCV Nucleoside Inhibitor RO5428029 in Healthy Subjects and in CHC Genotype 1 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This 2-part, randomized, double-blind, placebo-controlled study will assess the safety,
      pharmacokinetics and pharmacodynamics of RO5428029 in healthy volunteers and patients with
      hepatitis C infection. Cohorts will be randomized to receive either RO5428029 in ascending
      doses or placebo for up to 7 days (patients) or up to 14 days (healthy volunteers).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part B: Viral load response: HCV RNA (assessed by Roche COBAS Taqman HCV Test)</measure>
    <time_frame>up to 17 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts A + B: Safety: Incidence of adverse events</measure>
    <time_frame>up to 24 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts A + B: Pharmacokinetics: Area under the concentration - time curve (AUC)</measure>
    <time_frame>up to 24 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part B: Viral resistance (viral breakthrough/non-response/partial response) HCV RNA assessed by Roche COBAS Paqman HCV Test</measure>
    <time_frame>up to 17 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Hepatitis C, Chronic, Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>A1 Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B1 HCV Infection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5428029</intervention_name>
    <description>Multiple ascending doses</description>
    <arm_group_label>A1 Healthy Volunteers</arm_group_label>
    <arm_group_label>B1 HCV Infection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>multiple doses</description>
    <arm_group_label>A2</arm_group_label>
    <arm_group_label>B2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects (Part A) or patients with chronic hepatitis C infection (Part B), 18
             to 60 years of age, inclusive

          -  Body mass index (BMI) between 18 and 32 kg/m2, inclusive, and a minimum weight of 45
             kg

          -  Female subjects/patients must be surgically sterile or post-menopausal

          -  Male subjects/patients and their partners of childbearing potential must use 2 methods
             of contraception

          -  For HCV patients:

          -  Hepatitis C genotype 1 of &gt; 6 months duration at screening

          -  HCV RNA quantifiable (Roche COBAS TaqMan HCV Test) at screening

          -  HCV treatment-naïve (no prior antiviral therapy for chronic hepatitis C with
             interferon-based therapy)

          -  Liver biopsy or non-invasive procedure within the past 2 years showing absence of
             cirrhosis

        Exclusion Criteria:

          -  Pregnant or lactating women, and male partners of women who are pregnant or lactating

          -  Positive test for drugs of abuse

          -  History (within 3 months of screening) of alcohol consumption exceeding 2 standard
             drinks per day on average (1 standard drink = 10 grams or 1 unit of alcohol

          -  History or symptoms of any significant disease or disorder

          -  History of active malignancy within the last 5 years, except for localized or in situ
             carcinoma (e.g. basal or squamous cell carcinoma of the skin)

          -  Positive for hepatitis B or HIV infection, and/ or for HCV for healthy volunteers
             (Part A)

          -  For HCV patients:

          -  Decompensated liver disease or impaired liver function as defined by any history of
             ascites, hepatic encephalopathy, hepatocellular carcinoma or bleeding esophageal
             varices, or prothrombin international normalized ratio (PTINR) &gt;/= 2.0 at screening

          -  Evidence of cirrhosis and/or incomplete transition to cirrhosis

          -  Presence or history of non-hepatitis C liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <zip>34094</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <zip>67064</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chorzow</city>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsaw</city>
        <zip>01-201</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wrocław</city>
        <zip>50-349</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Netherlands</country>
    <country>Poland</country>
  </location_countries>
  <removed_countries>
    <country>Romania</country>
  </removed_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2011</study_first_submitted>
  <study_first_submitted_qc>June 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2011</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

